Company intelligence / Profile preview

BioSavita

Plymouth, MI, USA

Ownership: Private
Employees: ~6
Development stage: Other

Overview

BioSavita licenses its yeast-based platform for biosimilar antibody production; one internal program is anti-CD52 (similar to Campath) for multiple sclerosis and leukemia.

Therapeutic areas: OncologyNeurology
Modalities: Monoclonal antibodyAntibody-drug conjugateFusion proteinRecombinant protein
Industry: Biotech

Partnerships

Six of the top twenty biopharma companies (licensees)

Beyond the preview

Go deeper on BioSavita.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSavita.

Explore the full profile